Home > > > Report Detail

Global Monoclonal antibodies (mAbs) Biosimilars Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Publisher Name :
Date: 11-Nov-2022
No. of pages: 97
Inquire Before Buying

Report Scope

This latest report researches the industry structure, revenue and gross margin. Major players' headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Monoclonal antibodies (mAbs) Biosimilars companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

This report also includes a discussion of the major players across each regional Monoclonal antibodies (mAbs) Biosimilars market. Further, it explains the major drivers and regional dynamics of the global Monoclonal antibodies (mAbs) Biosimilars market and current trends within the industry.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

- Biocon

- Celltrion

- Dr. Reddy's Laboratories

- Hospira

- 3SBio

- Accord Healthcare

- AET Biotech

- Allergan

- Amega Biotech

Market Segments

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.

Monoclonal antibodies (mAbs) Biosimilars Segment by Type

- Erythropoietin (EPO)

- Human Growth Hormone (HGH)

- Granulocyte- Colony Stimulating Factor (G-CSF)

- Monoclonal Antibody (mAb)

- Insulin

- Interferon (IFN)

- Others

Monoclonal antibodies (mAbs) Biosimilars Segment by Application

- Anti-Cancer

- Anti-Inflammatory/Autoimmune

Key Regions & Countries

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Russia

- - Nordic Countries

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - Southeast Asia

- - India

- - Australia

- - Rest of Asia

- Latin America

- - Mexico

- - Brazil

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Monoclonal antibodies (mAbs) Biosimilars market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:

This report presents an overview of global market for Monoclonal antibodies (mAbs) Biosimilars market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Monoclonal antibodies (mAbs) Biosimilars, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Monoclonal antibodies (mAbs) Biosimilars, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Monoclonal antibodies (mAbs) Biosimilars revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Monoclonal antibodies (mAbs) Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Monoclonal antibodies (mAbs) Biosimilars revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, 3SBio, Accord Healthcare, AET Biotech, Allergan and Amega Biotech, etc.

Global Monoclonal antibodies (mAbs) Biosimilars Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Erythropoietin (EPO)
1.2.3 Human Growth Hormone (HGH)
1.2.4 Granulocyte- Colony Stimulating Factor (G-CSF)
1.2.5 Monoclonal Antibody (mAb)
1.2.6 Insulin
1.2.7 Interferon (IFN)
1.2.8 Others
1.3 Market by Application
1.3.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Growth Rate by Application: 2017 VS 2021 VS 2028
1.3.2 Anti-Cancer
1.3.3 Anti-Inflammatory/Autoimmune
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size (2017-2028)
2.2 Monoclonal antibodies (mAbs) Biosimilars Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2017-2022)
2.4 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Forecast by Region (2023-2028)
2.5 Global Top Monoclonal antibodies (mAbs) Biosimilars Countries Ranking by Market Size
3 Monoclonal antibodies (mAbs) Biosimilars Competitive by Company
3.1 Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Players
3.1.1 Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Players (2017-2022)
3.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players (2017-2022)
3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue
3.4 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio
3.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2021
3.5 Global Monoclonal antibodies (mAbs) Biosimilars Key Players Head office and Area Served
3.6 Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
3.7 Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Revenue by Type (2017-2022)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Revenue by Type (2023-2028)
5 Global Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Application (2017-2022)
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2020-2022)
6.2 North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2028)
6.3 North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2028)
6.4 North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2020-2022)
7.2 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2028)
7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2028)
7.4 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2020-2022)
8.2 Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2028)
8.3 Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2028)
8.4 Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2020-2022)
9.2 Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2028)
9.3 Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2028)
9.4 Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2020-2022)
10.2 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2028)
10.3 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2028)
10.4 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Biocon
11.1.1 Biocon Company Details
11.1.2 Biocon Business Overview
11.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.1.4 Biocon Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
11.1.5 Biocon Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.1.6 Biocon Recent Developments
11.2 Celltrion
11.2.1 Celltrion Company Details
11.2.2 Celltrion Business Overview
11.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.2.4 Celltrion Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
11.2.5 Celltrion Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.2.6 Celltrion Recent Developments
11.3 Dr. Reddy's Laboratories
11.3.1 Dr. Reddy's Laboratories Company Details
11.3.2 Dr. Reddy's Laboratories Business Overview
11.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.3.4 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
11.3.5 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.3.6 Dr. Reddy's Laboratories Recent Developments
11.4 Hospira
11.4.1 Hospira Company Details
11.4.2 Hospira Business Overview
11.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.4.4 Hospira Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
11.4.5 Hospira Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.4.6 Hospira Recent Developments
11.5 3SBio
11.5.1 3SBio Company Details
11.5.2 3SBio Business Overview
11.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.5.4 3SBio Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
11.5.5 3SBio Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.5.6 3SBio Recent Developments
11.6 Accord Healthcare
11.6.1 Accord Healthcare Company Details
11.6.2 Accord Healthcare Business Overview
11.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.6.4 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
11.6.5 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.6.6 Accord Healthcare Recent Developments
11.7 AET Biotech
11.7.1 AET Biotech Company Details
11.7.2 AET Biotech Business Overview
11.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.7.4 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
11.7.5 AET Biotech Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.7.6 AET Biotech Recent Developments
11.8 Allergan
11.8.1 Allergan Company Details
11.8.2 Allergan Business Overview
11.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.8.4 Allergan Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
11.8.5 Allergan Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.8.6 Allergan Recent Developments
11.9 Amega Biotech
11.9.1 Amega Biotech Company Details
11.9.2 Amega Biotech Business Overview
11.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Products and Services
11.9.4 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
11.9.5 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
11.9.6 Amega Biotech Recent Developments
12 Monoclonal antibodies (mAbs) Biosimilars Market Dynamics
12.1 Monoclonal antibodies (mAbs) Biosimilars Market Trends
12.2 Monoclonal antibodies (mAbs) Biosimilars Market Drivers
12.3 Monoclonal antibodies (mAbs) Biosimilars Market Challenges
12.4 Monoclonal antibodies (mAbs) Biosimilars Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
List of Tables
Table 1. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Erythropoietin (EPO)
Table 3. Key Players of Human Growth Hormone (HGH)
Table 4. Key Players of Granulocyte- Colony Stimulating Factor (G-CSF)
Table 5. Key Players of Monoclonal Antibody (mAb)
Table 6. Key Players of Insulin
Table 7. Key Players of Interferon (IFN)
Table 8. Key Players of Others
Table 9. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 10. Global Monoclonal antibodies (mAbs) Biosimilars Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 11. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Region (2017-2022)
Table 13. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Players (2017-2022) & (US$ Million)
Table 14. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players (2017-2022)
Table 15. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2021)
Table 16. Ranking of Global Top Monoclonal antibodies (mAbs) Biosimilars Companies by Revenue (US$ Million) in 2021
Table 17. Global 5 Largest Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue (CR5 and HHI) & (2017-2022)
Table 18. Key Players Headquarters and Area Served
Table 19. Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
Table 20. Date of Key Manufacturers Enter into Monoclonal antibodies (mAbs) Biosimilars Market
Table 21. Mergers & Acquisitions, Expansion Plans
Table 22. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2017-2022) & (US$ Million)
Table 23. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2017-2022)
Table 24. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 25. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2023-2028)
Table 26. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2017-2022) & (US$ Million)
Table 27. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2017-2022)
Table 28. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 29. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2023-2028)
Table 30. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2020-2022) & (US$ Million)
Table 31. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 32. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 33. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 34. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 35. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 36. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2023-2028) & (US$ Million)
Table 37. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2020-2022) & (US$ Million)
Table 38. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 39. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 40. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 41. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 42. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 43. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2020-2022) & (US$ Million)
Table 45. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 46. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 47. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 48. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 49. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 50. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Region (2023-2028) & (US$ Million)
Table 51. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2020-2022) & (US$ Million)
Table 52. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 53. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 54. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 55. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 56. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 57. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Company (2020-2022) & (US$ Million)
Table 59. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 63. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 64. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Country (2023-2028) & (US$ Million)
Table 65. Biocon Company Details
Table 66. Biocon Business Overview
Table 67. Biocon Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 68. Biocon Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 69. Biocon Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 70. Biocon Recent Developments
Table 71. Celltrion Company Details
Table 72. Celltrion Business Overview
Table 73. Celltrion Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 74. Celltrion Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 75. Celltrion Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 76. Celltrion Recent Developments
Table 77. Dr. Reddy's Laboratories Company Details
Table 78. Dr. Reddy's Laboratories Business Overview
Table 79. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 80. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 81. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 82. Dr. Reddy's Laboratories Recent Developments
Table 83. Hospira Company Details
Table 84. Hospira Business Overview
Table 85. Hospira Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 86. Hospira Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 87. Hospira Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 88. Hospira Recent Developments
Table 89. 3SBio Company Details
Table 90. 3SBio Business Overview
Table 91. 3SBio Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 92. 3SBio Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 93. 3SBio Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 94. 3SBio Recent Developments
Table 95. Accord Healthcare Company Details
Table 96. Accord Healthcare Business Overview
Table 97. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 98. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 99. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 100. Accord Healthcare Recent Developments
Table 101. AET Biotech Company Details
Table 102. AET Biotech Business Overview
Table 103. AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 104. AET Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 105. AET Biotech Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 106. AET Biotech Recent Developments
Table 107. Allergan Company Details
Table 108. Allergan Business Overview
Table 109. Allergan Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 110. Allergan Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 111. Allergan Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 112. Allergan Recent Developments
Table 113. Amega Biotech Company Details
Table 114. Amega Biotech Business Overview
Table 115. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Services
Table 116. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022) & (US$ Million)
Table 117. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars SWOT Analysis
Table 118. Amega Biotech Recent Developments
Table 119. Monoclonal antibodies (mAbs) Biosimilars Market Trends
Table 120. Monoclonal antibodies (mAbs) Biosimilars Market Drivers
Table 121. Monoclonal antibodies (mAbs) Biosimilars Market Challenges
Table 122. Monoclonal antibodies (mAbs) Biosimilars Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Type: 2021 VS 2028
Figure 2. Erythropoietin (EPO) Features
Figure 3. Human Growth Hormone (HGH) Features
Figure 4. Granulocyte- Colony Stimulating Factor (G-CSF) Features
Figure 5. Monoclonal Antibody (mAb) Features
Figure 6. Insulin Features
Figure 7. Interferon (IFN) Features
Figure 8. Others Features
Figure 9. Global Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Application: 2021 VS 2028
Figure 10. Anti-Cancer Case Studies
Figure 11. Anti-Inflammatory/Autoimmune Case Studies
Figure 12. Monoclonal antibodies (mAbs) Biosimilars Report Years Considered
Figure 13. Global Monoclonal antibodies (mAbs) Biosimilars Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Monoclonal antibodies (mAbs) Biosimilars Market Size 2017-2028 (US$ Million)
Figure 15. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Market Share by Region: 2021 VS 2028
Figure 16. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Region in 2017 VS 2022
Figure 17. Global Top 10 Monoclonal antibodies (mAbs) Biosimilars Countries Ranking by Market Size (US$ Million) in 2021
Figure 18. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players in 2021
Figure 19. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2021)
Figure 20. The Top 10 and 5 Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2021
Figure 21. North America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Company in 2021
Figure 22. North America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2017-2028)
Figure 23. North America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2017-2028)
Figure 24. North America Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Country (2017-2028)
Figure 25. U.S. Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 26. Canada Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 27. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Company in 2021
Figure 28. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2017-2028)
Figure 29. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2017-2028)
Figure 30. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Country (2017-2028)
Figure 31. Germany Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 32. France Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 33. U.K. Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 34. Italy Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 35. Russia Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 36. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Company in 2021
Figure 37. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2017-2028)
Figure 38. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2017-2028)
Figure 39. Asia Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Region (2017-2028)
Figure 40. China Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 41. Japan Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 42. South Korea Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 43. India Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 44. Australia Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 45. Taiwan Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 46. Indonesia Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 47. Thailand Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 48. Malaysia Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 49. Philippines Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 50. Vietnam Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 51. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Company in 2021
Figure 52. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2017-2028)
Figure 53. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2017-2028)
Figure 54. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Country (2017-2028)
Figure 55. Mexico Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 56. Brazil Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 57. Argentina Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 58. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Company in 2021
Figure 59. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2017-2028)
Figure 60. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2017-2028)
Figure 61. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Country (2017-2028)
Figure 62. Turkey Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 63. Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 64. U.A.E Monoclonal antibodies (mAbs) Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 65. Biocon Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 66. Celltrion Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 67. Dr. Reddy's Laboratories Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 68. Hospira Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 69. 3SBio Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 70. Accord Healthcare Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 71. AET Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 72. Allergan Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 73. Amega Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2017-2022)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs